SA carries a low risk of major complications and high immediate technical success. Poor long-term patency suggests that SA is not as durable as bypass surgery. However, failed SA did not compromise subsequent surgery, which only became necessary in a proportion of patients. Our data suggests that there is little to be lost by using SA as first-line treatment for patients with limb-threatening ischaemia who are poor operative risks or who have no autologous vein available.

No abstract

Pelvic exenteration (PE) is a radical procedure involving the resection of multiple pelvic viscera for primary and recurrent pelvic malignancies. The median 5-year overall survival for those with locally advanced and locally recurrent rectal cancers undergoing PE has been reported at 38% and 28%, respectively [1,2], and for gynaecological cancers it is 40% [3]. In the case of colorectal cancer, this compares with a 5-year survival of <5% without resection [4].

No abstract